Lilian Hwang
Medical · Arcadia, CANPI 1619321858
Payments from drug & device makers
Across 91 payments — averaging $42.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$448
- Pfizer$437
- Sanofi$374
- AbbVie$366
- Dermavant Sciences, Inc.$353
- Galderma Laboratories, L.p.$344
- plus $2K from 15 others
What the payments were for
- Food & beverage$3,47290%
- Education$39110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 11 | $448 |
| Pfizer | 6 | $437 |
| Sanofi | 9 | $374 |
| AbbVie | 17 | $366 |
| Dermavant Sciences, Inc. | 8 | $353 |
| Galderma Laboratories, L.p. | 5 | $344 |
| Novartis | 3 | $264 |
| UCB, Inc. | 4 | $252 |
| LEO Pharma Inc. | 5 | $181 |
| Johnson & Johnson | 4 | $156 |
| Sun Pharmaceutical Industries Inc. | 2 | $133 |
| Regeneron Healthcare Solutions, Inc. | 4 | $121 |
| Arcutis Biotherapeutics, Inc. | 2 | $104 |
| E.r. Squibb & Sons, L.L.C. | 2 | $80 |
| Amgen | 3 | $62 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $60 |
| Merck | 1 | $32 |
| Genentech USA, Inc. | 1 | $27 |
| Pharmaessentia USA Corporation | 1 | $26 |
| Organon | 1 | $24 |
| Smith+Nephew | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,863 in reported general payments places this provider in the 80th percentile of 2,087 medical providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OtezlaApremilast | 33 | $166,117 |
| Fluorouracil | 49 | $3,224 |
| Tacrolimus | 24 | $2,603 |
| Ketoconazole | 146 | $2,380 |
| Clobetasol Propionate | 34 | $1,058 |
| Triamcinolone Acetonide | 95 | $825 |
| Clindamycin Phosphate | 26 | $650 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 31 | $535 |
| Gentamicin Sulfate | 12 | $458 |
| Clotrimazole | 17 | $390 |
| Doxycycline Hyclate | 25 | $312 |
| Imiquimod | 11 | $264 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 23 | $177 |
| Mupirocin | 22 | $176 |
| Ammonium Lactate | 14 | $172 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $62 | $166,11733 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,087 medical providers in California.
Other medical in Arcadia
- Andrew ImbusArcadia$33K
- Nicola LowreyOrange$655K
- Justin LoveLoma Linda$553K
- David DoriguzziLancaster$514K
- Alison GracomIrvine$467K
- Jeffrey BonnaudLos Angeles$314K
- Ana TorresLaguna Beach$229K
- Heather ParlettRedlands$168K
- Deirdre MoxleyFullerton$149K
- Tri leGardena$127K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.